脉络膜渗漏：达雷妥尤单抗的一种罕见且不常见的并发症。
Choroidal effusion: a rare and unusual complication of daratumumab.
机构信息
Hematology Oncology, Ascension St John Hospital, Detroit, Michigan, USA
Internal Medicine, Ascension St John Hospital, Detroit, Michigan, USA.
出版信息
BMJ Case Rep. 2022 Aug 1;15(8):e249735. doi: 10.1136/bcr-2022-249735.
Abstract
Daratumumab-containing regimens are an effective treatment for advanced cases of multiple myeloma. Overall, daratumumab has a favourable safety profile, although rare side effects can occur. Rare side effects of daratumumab include choroidal effusion. Patients who begin to experience symptoms such as eye swelling, vision changes, eye discharge and blurry vision should undergo urgent ophthalmological evaluation and their daratumumab infusions held.
摘要
含达雷妥尤单抗的方案是多发性骨髓瘤晚期的有效治疗方法。总体而言，达雷妥尤单抗具有良好的安全性，但也可能出现罕见的副作用。达雷妥尤单抗罕见的副作用包括脉络膜渗出。开始出现眼部肿胀、视力改变、眼部分泌物和视力模糊等症状的患者应立即进行眼科评估，并暂停达雷妥尤单抗输注。
相似文献
1
Choroidal effusion: a rare and unusual complication of daratumumab.脉络膜渗漏：达雷妥尤单抗的一种罕见且不常见的并发症。
BMJ Case Rep. 2022 Aug 1;15(8):e249735. doi: 10.1136/bcr-2022-249735.
2
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.新型单克隆抗体治疗复发/难治性多发性骨髓瘤疗效与安全性的系统评价和荟萃分析
Oncotarget. 2017 May 16;8(20):34001-34017. doi: 10.18632/oncotarget.16987.
3
Association of Choroidal Effusion and Infusion of Daratumumab.达雷妥尤单抗输注与脉络膜积液的关联
JAMA Ophthalmol. 2019 Jul 1;137(7):853-854. doi: 10.1001/jamaophthalmol.2019.1427.
4
[Acute bilateral angle closure glaucoma and choroidal effusion associated with daratumumab administration for the treatment of multiple myeloma].[急性双侧闭角型青光眼和脉络膜积液与达雷妥尤单抗治疗多发性骨髓瘤相关]
J Fr Ophtalmol. 2023 May;46(5):552-553. doi: 10.1016/j.jfo.2022.07.004. Epub 2023 Apr 13.
5
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.达雷妥尤单抗治疗多发性骨髓瘤：多发性骨髓瘤 GIMEMA 拉齐奥组的经验。
Ann Hematol. 2021 Apr;100(4):1059-1063. doi: 10.1007/s00277-020-04374-y. Epub 2021 Feb 2.
6
Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.优化接受达雷妥尤单抗为基础方案治疗的多发性骨髓瘤患者的输血管理。
Transfusion. 2021 Jul;61(7):2054-2063. doi: 10.1111/trf.16425. Epub 2021 May 7.
7
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
8
Daratumumab for the treatment of multiple myeloma.达雷妥尤单抗用于治疗多发性骨髓瘤。
Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2.
9
Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
10
Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature.达雷妥尤单抗引起的脉络膜积液：一例病例报告及文献综述
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):e994-e997. doi: 10.1016/j.clml.2020.08.030. Epub 2020 Sep 19.
本文引用的文献
1
Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion.单克隆抗体（达雷妥尤单抗）输注引起的急性双侧房角关闭
Am J Ophthalmol Case Rep. 2021 Mar 26;22:101079. doi: 10.1016/j.ajoc.2021.101079. eCollection 2021 Jun.
2
Multiple myeloma.多发性骨髓瘤。
Lancet. 2021 Jan 30;397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
3
Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature.达雷妥尤单抗引起的脉络膜积液：一例病例报告及文献综述
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):e994-e997. doi: 10.1016/j.clml.2020.08.030. Epub 2020 Sep 19.
4
Bilateral Secondary Angle Closure During Daratumumab Infusion: A Case Report and Review of the Literature.在达雷妥尤单抗输注期间发生双侧闭角型青光眼：病例报告及文献复习。
J Glaucoma. 2020 Aug;29(8):e83-e86. doi: 10.1097/IJG.0000000000001562.
5
Daratumumab: a game changer in myeloma therapy.达雷妥尤单抗：骨髓瘤治疗的变革者。
Lancet Haematol. 2020 Jun;7(6):e426-e427. doi: 10.1016/S2352-3026(20)30105-8.
6
Association of Choroidal Effusion and Infusion of Daratumumab.达雷妥尤单抗输注与脉络膜积液的关联
JAMA Ophthalmol. 2019 Jul 1;137(7):853-854. doi: 10.1001/jamaophthalmol.2019.1427.
7
Daratumumab-induced transient myopic shift.达雷妥尤单抗诱导的短暂性近视性移位。
Am J Ophthalmol Case Rep. 2018 Dec 18;13:116-118. doi: 10.1016/j.ajoc.2018.12.017. eCollection 2019 Mar.
8
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.多发性骨髓瘤中新单克隆抗体输注反应的管理：达雷妥尤单抗和埃罗妥珠单抗。
J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143.
9
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
10
CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus.CD38和CD157胞外酶标记人角膜缘中的细胞亚群。
Mol Med. 2009 Mar-Apr;15(3-4):76-84. doi: 10.2119/molmed.2008.00108. Epub 2008 Nov 19.
Zotero 插件